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BACKGROUND: Fusion of the carboxyterminal peptide (CTP) of hCG to FSH results in a follitropin agonist with
an extended half-life, presumably due to the four O-oligosaccharides on the CTP. Alternatively, an rhFSH analogue
containing additional N-linked carbohydrate is described in this report. METHODS: A DNA sequence containing
two N-oligosaccharide signal sequences was ligated into a vector containing hFSHb- and a-subunit encoding cDNA,
and expressed in CHO-K1 cells. In-vitro bioactivity of the single-chain hormone was assessed in CHO cells express-
ing the hFSH receptor. Pharmacokinetic values were derived from serial serum assays of the analogue in immature
female rats following a single i.v. injection. In-vivo bioactivity was assessed by measuring ovarian weight gain 3 days
post-injection. RESULTS: rhFSH-N2 and native rhFSH induced comparable levels of cAMP in vitro. t1/2 for native
rhFSH, rhFSH-CTP and rhFSH-N2 were 3.7, 7.1 and 7.3 h respectively. Rats receiving rhFSH-N2 had a mean 6
SD ovarian weight 3 days post-i.v. injection (22 6 3.6 mg) signi®cantly greater than rats receiving rhFSH and saline
(16.7 6 1.5 and 15.3 6 0.47 mg respectively, P < 0.05). CONCLUSIONS: rhFSH-N2 has prolonged half-life and
increased bioactivity compared with native rhFSH. This rhFSH agonist, and other analogues containing additional
N-oligosaccharides may have important clinical applications.
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Introduction
Exogenous gonadotrophin therapy remains a mainstay of
treatment for couples having dif®culty conceiving. Prolonged
therapy is necessary to achieve a therapeutic effect, typically
for 8±10 consecutive days to stimulate folliculogenesis in
women and for several months as replacement therapy in
hypogonadotrophic males to induce spermatogenesis.
Recombinant hFSH is administered as an i.m. or s.c. daily
injection, with consequent discomfort and potential for local
injection site reaction. Decreasing the frequency of adminis-
tration would facilitate therapy and render gonadotrophin
administration more tolerable.
Two long-acting gonadotrophin agonists developed by
fusing the carboxyterminal peptide of hCG (CTP) to native
recombinant human FSH (rhFSH) either as a non-covalently
bound heterodimer containing the common a- and b-FSH
subunits (Fares et al., 1992) or as a contiguous peptide (Klein
et al., 2002) have previously been reported. The increased half-
life and biopotency of this analogue (rhFSH-CTP) is speculated
to be due to the four O-linked glycosylation sites present on the
CTP moiety (Matzuk et al., 1990). Alternatively, the biology of
an FSH analogue containing additional N-linked oligosacchar-
ides has not been reported.
Addition of carbohydrate to the peptide backbone is a post-
translational event that may occur through O-linkage with
serine or threonine residues, or via N-linkage to asparagine.
Whereas the glycosylation signal sequence for O-linked sugars
is poorly de®ned, addition of N-linked carbohydrates to
asparagine occurs whenever the primary amino acid sequence
contains the trimer Asn-X-Ser/Thr, where X denotes any amino
acid except proline (Imperiali and O'Connor, 1999). The
number of N-linked carbohydrates that are introduced in a
synthetic polypeptide chain can thus be precisely de®ned.
Consequently, this represents a potentially more powerful tool
to re®ne the pharmacokinetic properties of rhFSH and perhaps
other recombinant species in a clinically meaningful way,
compared with adding CTP or other sequences containing
clusters of O-linked sugars. To determine the feasibility of this
approach, we designed a synthetic oligopeptide containing two
copies of the N-linked glycosylation signal sequence, and
tethered this sequence between the b- and a-subunits of hFSH,
creating a single-chain fusion hormone analogue (rhFSH-N2).
The ability of this novel construct to bind and activate the
hFSH receptor in vitro, and the in-vivo activity and half-life of
this analogue compared to native recombinant hFSH and
hFSH-CTP, were examined.
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All enzymes for recombinant DNA were purchased from New
England Biolabs (Beverly, MA, USA). The Columbia University Core
Laboratory synthesized DNA primers for PCR. cDNA for hFSHb and
the common a-subunit were provided by Dr William Moyle (Robert
Wood Johnson Medical School, Piscataway, NJ, USA). PCR reactions
were performed with Vent DNA polymerase (primer sequences are
available upon request) and all products of the reactions were
sequenced to ensure that no mutations were introduced during the
ampli®cation process. Ligation reactions were transformed into E. coli
strain DH5a, and DNA clones grown in standard Luria±Bertani
medium for large-scale plasmid preparation. Transformation of DH5a
was performed according to standard techniques with calcium
chloride.
Controls
Native rhFSH (follitropin-b) was generously provided by Serono, Inc.
(Rockland, MD, USA). Single-chain rhFSH-CTP was produced in a
CHO-K1 cell line as described previously (Klein et al., 2002).
Construction of a rhFSHb-N2-a (rhFSH-N2) single-chain fusion
clone
Two complementary DNA strands encoding the following polypep-
tide sequence were synthesized by Columbia's protein core: Ser-Gly-
Ser-Asn-Ala-Thr-Gly-Ser-Gly-Ser-Asn-Ala-Thr-Ser-Gly-Ser, such
that following annealing of the strands 5¢ BamHI and 3¢ SpeI sticky
ends were formed (DNA sequences available upon request). The
synthetic DNA duplex was then ligated into a vector along with the
rhFSHb- and a-subunit cDNA. The in-frame ligation of these three
DNA was accomplished by placing a XhoI site immediately preceding
the start codon and replacing the terminator codon of the hFSH b-
subunit with a BamHI site. In addition a SpeI site was placed at the 5¢
end and a SacI site immediately following the terminator codon of the
a-subunit. The three fragments were then inserted into an SV40-based
expression vector at XhoI/SacI sites to form the rhFSH-N2 expression
construct (Figure 1).
Expression and puri®cation of rhFSH-N2
An SV40 expression clone containing the fusion construct was co-
transfected into CHO-K1 cells along with an SV2neo clone encoding
resistance to G418. The CHO cell transformation was performed using
a standard calcium phosphate precipitate technique. Selectable media
containing G418 (Gemini Bioproducts, Woodland, CA, USA) were
used to isolate colonies that were pooled and maintained in Ham's F-
12 containing 500 mg/ml G418, 10% fetal bovine serum, 100 IU/ml
penicillin, 100 mg/ml streptomycin, and 4 mmol/l glutamine. Pooled
colonies were subcloned in 96-well microtitre dishes to isolate a high-
secreting clone. To further increase yields cells, were grown in
suspension cultures, with spinner bottles seeded at 105 cells/ml in
CHO-S-SFM II (Life Technologies, Rockville, MD, USA) containing
400 mg/ml G418. Cultures generally reached a density of 23106 cells/
ml on day 6 or 7, and the cell supernatant was harvested on day 7 or 8.
Supernatants received 0.2 mmol/l phenylmethylsulphonyl ¯uoride and
were ®ltered through a 0.2 mm membrane and kept at 4°C until the day
of puri®cation.
Af®nity puri®cation of rhFSH-N2 was accomplished using an a-
speci®c monoclonal antibody column [A103 (O'Connor et al., 1994)].
The column was prepared by coupling puri®ed A103 immunoglobu-
lins to cyanogen bromide (CNBr)-Sepharose-4B according to the
manufacturer's instructions (Amersham Pharmacia Biotech,
Piscataway, NJ, USA) at a concentration of 5 mg antibody/ml
Sepharose. After applying the cell supernatant, the column was
washed with 50 bed volumes of PBS followed by 2 bed volumes of
distilled water. rhFSH-N2 was eluted with 3 or 4 bed volumes of 1
mol/l acetic acid and immediately dried on a Speed-Vac concentrator
(Savant Instruments, Holbrook, NY, USA).
Electrophoresis and Western blotting
Sodium dodecyl sulphate±polycrylamide gel electrophoresis was
performed and proteins were transferred to nitrocellulose using
standard techniques (Laemmli, 1970; Towbin et al., 1979; Burnette,
1981). After blocking, the nitrocellulose was incubated overnight in a
1:10 000 dilution of a monoclonal antibody to FSH-b from Biodesign
International (Saco, ME, USA). The membrane was then washed and
incubated for 1 h in a 1:10 000 dilution of a peroxidase-conjugated
polyclonal antibody to mouse immunoglobulins (Amersham±
Pharmacia Biotech). After washing, the nitrocellulose was incubated
in a chemiluminescent detection reagent according to the manufac-
turer's directions (Amersham Pharmacia). Bands were visualized by
exposure to X-ray ®lm.
Isoelectric focusing gel electrophoresis
Samples were electrophoresed on a Novex pre-cast IEF gel, with a pI
range of pH 3±7 according to the manufacturer's instructions
(Invitrogen, Carlsbad, CA, USA) and then visualized by silver
staining.
In-vitro bioactivity
The rhFSH-N2 was quanti®ed using an hFSH-b speci®c antibody
(Biodesign International, Saco, ME, USA) radioimmunoassay.
Biological activity was assessed using CHO cells transfected with
the FSH receptor (CHO FSHr) as previously described (Kelton et al.,
1992). A total of 23104 cells was mixed with rhFSH-N2, rhFSH-CTP
or rhFSH at varying concentrations in a total volume of 200 ml.
Figure 1. Schematic of rhFSH-N2 construct and associated
restriction sites. A polypeptide-encoding DNA sequence containing
two N-glycosylation signal sequences was used to tether the a- and
b-subunits of hFSH.
Figure 2. Non-reduced western Blot showing migration of
rhFSH-N2, rhFSH-CTP and rhFSH in 10% sodium dodecyl
sulphate±acrylamide gel. (Note the lack of dissociation of the b-























Mixtures were incubated at 37°C for 15 min, and cAMP levels were
measured using a radioimmunoassay kit (Perkin Elmer Life Sciences,
Boston, MA, USA).
In-vivo bioactivity and half-life determinations
Approval was obtained from the Institutional Animal Care and Use
Committee at Columbia University. Immature (21 day old) female
Sprague±Dawley rats were obtained from Charles River Laboratories
(Wilmington, MA, USA). Rats were housed three to a cage and given
standard food and tap water ad libitum. Animals were randomly
assigned to one of four treatment groups: rhFSH-N2, single-chain
recombinant hFSH tethered to CTP (rhFSH-CTP), rhFSH, or saline.
All hormones were diluted to 11 mg/ml using injection buffer
containing bovine serum albumin (1 mg/ml). Hormone was admin-
istered as a single i.v. dose of 2800 ng/rat in 0.25 ml of solution via a
dorsal tail vein. Serum was obtained by periorbital venipuncture at the
following intervals post-injection: 0.5, 1.0, 3.0, 6.0 and 12 h.
Anaesthesia with iso¯urane was administered prior to injection and
each bleed. Serum was assayed for hFSH by enzyme-linked
immunosorbent assay (Diagnostic Systems Laboratory, Webster,
TX, USA). Rats were killed 72 h post-injection by carbon dioxide
inhalation followed by exsanguination via cardiac puncture. Ovaries
were then extirpated and weighed.
Pharmacokinetic analysis was performed using Winnonlin 1.0
software (Pharsight Corporation, Mountain View, CA, USA). Mean
values for each time-point within a group were used to estimate
pharmacokinetic parameters for terminal (elimination) half-life (t1/2)
and area under the serum concentration±time curve (AUC). Clearance
(Cl) was calculated using the relationship Cl = dose/AUC.
Statistical analysis
Mean ovarian plasma concentrations and ovarian weights were
compared between groups in a one-way analysis of variance
(ANOVA) model. Since groups with higher means tended to also
have higher variances, the data were ®rst log-transformed to stabilize
the variance between groups and satisfy the model assumptions. The
primary comparison of interest was between rhFSH-N2 and rhFSH,
and this difference was tested using a single contrast within the one-
way structure. In addition, mean serum plasma concentrations at all
time-points were compared using a one-way ANOVA model. At each
time-point, the comparisons of interest were rhFSH-N2 versus rhFSH
and rhFSH-N2 versus rhFSH-CTP. These hypotheses were tested with
simultaneous contrasts at each time-point using a Bonferroni
adjustment to control for multiple comparisons, and the analysis for
each time-point was considered separately.
Results
A CHO cell clone producing 0.4 pmol/ml rhFSH-N2 was
isolated. Production increased to 3 pmol/ml when cells were
grown in suspension culture. A Western blot revealed puri®ed
Figure 3. An isoelectric focusing gel, pH 6±3 silver-stained. Lanes
1±3 are pH standards; lane A: rhFSH; lane B: rhFSH-CTP; lane C:
rhFSH-N2.
Figure 4. In-vitro bioactivity, as assessed by induction of cAMP, of rhFSH, rhFSH-CTP and rhFSH-N2 in CHO cells expressing the FSH























rhFSH-N2 migration corresponding to a molecular size of
~58 kDa. This species migrated at a similar size to rhFSH-CTP,
yet larger than native rhFSH, consistent with increased mass
due to additional glycosylation (Figure 2). Isoelectric focusing
gel electrophoresis showed that both rhFSH-CTP and rhFSH-
N2 have a more acidic pro®le than rhFSH. There were ®ve
major isoforms for rhFSH between pI 4.3 and 4.9 and for
rhFSH-N2 between 4.05 and 4.8, while rhFSH-CTP focused
predominately as a smear between pI 3.85 and 4.55 (Figure 3).
In-vitro bioactivity
Binding of rhFSH-N2 to the hFSH receptor and signal
transduction was con®rmed by induction of cAMP in CHO
cells expressing the hFSH receptor. rhFSH-N2 induced a
similar rise in cAMP levels in vitro compared with rhFSH and
rhFSH-CTP (Figure 4).
In-vivo bioactivity and half-life determinations
Mean ovarian weights following a single injection of rhFSH-
N2, rhFSH and saline are shown in Figure 5. The results of the
simultaneous contrast testing indicated signi®cant differences
in the mean log ovarian weight in animals receiving rhFSH-N2
as compared with those receiving rhFSH (P < 0.025). There
was no signi®cant difference between ovarian weights from
rats receiving rhFSH-N2 and rhFSH-CTP (Figure 6).
Mean serum concentration±time curves for rhFSH-N2,
rhFSH-CTP and rhFSH are shown in Figure 7. Pharmaco-
kinetic parameter estimates are listed in Table I. The elimin-
ation half-life of rhFSH-N2 (7.3 h) was comparable with that of
rhFSH-CTP (7.1 h) and ~2-fold longer than rhFSH (3.7 h). The
amount of hormone present in the circulation at all time-points
post-injection was signi®cantly higher for rhFSH-N2 compared
with rhFSH. Mean plasma levels of rhFSH-N2 were not
signi®cantly different from those of rats receiving rhFSH-CTP,
although P-values were near the usual signi®cance level for
Figure 5. Mean ovarian weight from 21 day old female rats 3 days
post-i.v. injection of rhFSH-N2, rhFSH and saline (n = 3 for each
group).
Figure 6. Mean ovarian weight from 21 day old female rats 3 days
post-i.v. injection of rhFSH-N2 and rhFSH-CTP (n = 3 for each
group).
Figure 7. Mean (n = 3) serum concentration±time pro®les following a single i.v. injection of rhFSH, rhFSH-CTP and rhFSH-N2 (2800 ng/






















later time-points (0.057 and 0.062 for time-points 6 and 12 h
respectively) (Table II).
Discussion
Current recombinant gonadotrophin preparations are generally
administered as daily injections due to their relatively short
half-life. A long-acting follitropin agonist employing a CTP
tether to the carboxyterminus of FSHb (rhFSH-CTP) is
currently under development to provide a more convenient
dosing schedule for clinical use. The CTP contains a series of
four tightly spaced O-oligosaccharides, which are presumed to
be responsible for delaying hormone metabolism in vivo
(Matzuk et al., 1990). rhFSH-CTP has been shown to have an
elimination half-life 2±4-fold longer than native recombinant
hFSH (Klein et al., 2002), and a phase I trial in 12
hypogonadotrophic men supported the safety of this product
(Bouloux et al., 2001). However, the pharmacodynamic effect
of rhFSH-CTP in women has not been reported and the utility
of this fusion hormone in ovarian stimulation regimens remains
uncertain. Ovarian response to gonadotrophin stimulation is
highly variable, and is dependent on a number of factors
including patient age, ovarian reserve, and presence of
polycystic-appearing ovaries. rhFSH analogues with alterna-
tive half-lives may ultimately yield superior products for
clinical use in certain patient populations. For example,
patients with high sensitivity to gonadotrophins may require
an analogue with a shorter half-life, while a hypogonadotrophic
hypogonadal man requiring long-term replacement may bene®t
most from an extremely long-acting formulation.
Proteins are glycosylated by one of two distinct mechan-
isms: N-linkage via an amide group on asparagine, or O-
linkage, in which the oligosaccharide is attached to the
hydroxyl group on a serine or threonine residue. N-
Oligosaccharides share a common trimannosyl-chitobiose
core domain distinct from that of O-linked sugars, although
overall size and composition is variable (Dell and Morris,
2001). In addition to structural disparities, differences in the
function of native O-linked and N-linked oligosaccharides on
glycoprotein biology exist. For example, removal or deglyco-
sylation of the CTP of hCG, containing naturally occurring O-
oligosaccharides, increases metabolism of the hormone in vivo
(el-Deiry et al., 1989) but has no effect on proper folding of the
molecule and receptor activation. (el-Deiry et al., 1989;
Matzuk et al., 1990). In contrast, the native N-linked
oligosaccharides of hCG and the other glycoprotein hormones
play critical roles in both signal transduction and hormone
metabolism (Matzuk and Boime, 1988; Van Zuylen et al.,
1997; Imperiali and O'Connor, 1999).
Addition of the CTP, containing four O-linked oligosacchar-
ides, to rhFSH has been shown to increase the half-life of the
molecule without altering in-vitro bioactivity (and therefore
proper folding of the protein) (Klein et al., 2002). Lack of an
identi®able O-oligosaccharide consensus signal sequence,
however, limits precise adjustments in carbohydrate content
when designing hormone analogues. In an attempt to provide a
more ¯exible, well-de®ned means of delaying gonadotrophin
metabolism in vivo, we developed a recombinant follitropin
agonist containing additional N-linked carbohydrates on the
FSHb-subunit. Unlike O-linked sugars, the number of N-linked
moieties is easily modi®able in a synthetic oligopeptide
sequence by inserting a speci®ed number of consensus N-
oligosaccharide signal sequences. Adjusting the number of
added carbohydrates could theoretically result in FSH agonists
with a spectrum of pharmacokinetic characteristics and
bioactivity in vivo. These `designer gonadotrophin' formula-
tions may be tailored to meet the needs of speci®c patient
populations.
In this report, we examined the pharmacokinetics and
pharmacodynamics of a recombinant FSH analogue containing
two additional N-oligosaccharides to test the utility of this
approach. Stable, high-secreting CHO cell clones transfected
with our FSH analogue were isolated, and proper folding of the
fusion hormone was con®rmed using an in-vitro FSH bioassay.
Serum levels of rhFSH-N2 following i.v. administration
were comparable with that of rhFSH-CTP and signi®cantly
Table I. Mean pharmacokinetic parameter estimates for rhFSH, rhFSH-CTP
and rhFSH-N2 following i.v. injection of material at a dose of 2800 ng/rat
(n = 3 per group) to immature female rats (21 days old)
Parameter rhFSH rhFSH-CTP rhFSH-N2
AUC0±¥ (ng/h/ml) 1491 3887 4802
t1/2 (elimination) (h) 3.7 7.1 7.3
Clearance (ml/h) 1.9 0.72 0.58
CTP = carboxyterminal peptide; AUC = area under the curve; N2 = tether
containing two N-oligosaccharide sequences.
Table II. Comparison of mean serum concentrations of rats receiving rhFSH-N2 with those receiving rhFSH and rhFSH-CTP at all time-points post-i.v.
injection of hormone (2800 ng), along with observed signi®cance level using contrasts in the one-way layout with Bonferroni corrections for multiple
comparisonsa
Time (h) rhFSH-N2 (ng/ml) rhFSH (ng/ml) rhFSH-CTP (ng/ml)
Mean 6 SD Mean 6 SD P Mean 6 SD P
0.5 845 6 187.8 540 6 40.1 0.053 958.8 6 111 NS
1 747 6 73.2 299.2 6 36.4 0.00012 635.8 6 51 NS
3 467 6 129 119.1 6 77 0.0074 343.5 6 55.6 NS
6 324 6 65 53.6 6 21 0.00059 220 6 34.1 0.057
12 198 6 42 21.2 6 7.1 0.0036 137.7 6 14.6 0.062
aEach time-period considered as a separate analysis.






















increased relative to native recombinant FSH, con®rming the
ability of added N-oligosaccharides to decrease clearance of
FSH in a manner analogous to a CTP moiety. Pharmacokinetic
analysis of the data indicates rhFSH-N2 has a half-life ~2-fold
that of native rhFSH and increased in-vivo bioactivity relative
to native rhFSH following an i.v. bolus dose of hormone.
The altered in-vivo characteristics of rhFSH-N2 are most
likely related to the increased carbohydrate load present on the
peptide linker sequence used to covalently bind the two
subunits. N-Linked oligosaccharides on native hFSH are
known to confer protein stability, and FSH analogues contain-
ing added O-linked carbohydrates attached exclusively to the
b-subunit (without covalent binding to the common a-subunit)
have prolonged half-lives compared with native hFSH
(Bouloux et al., 2001). Furthermore, while both single-chain
rhFSH-CTP and rhFSH-CTP lacking a covalent linkage
between the subunits have never been compared, the pro-
longation in serum half-life relative to control rhFSH appears
comparable (2±3-fold increase) (Bouloux et al., 2001; Klein
et al., 2002). Nevertheless, the covalent bond between the two
subunits of rhFSH-N2 may play a contributory role in
conferring increased biopotency to our hormone analogue,
independent of any alteration in carbohydrate load. By
stabilizing subunit interaction through covalent linkage,
deactivation of the intact heterodimer due to subunit dis-
sociation may theoretically be inhibited. This theory has yet to
be examined. Most single-chain glycoprotein hormone analo-
gues have typically employed a carbohydrate-rich sequence as
a tether between subunits, confounding the effect of covalent
binding per se on bioactivity. A single-chain rhFSH construct
devoid of any linker sequence was able to bind and activate the
hFSH receptor in vitro (Sugahara et al., 1996). A pharmaco-
kinetic comparison between this analogue and native hFSH
would help to clarify the role of single-chain assembly on
hormone metabolism. The role of the peptide backbone of the
linker sequence must also be resolved. We plan to perform a
pharmacokinetic and pharmacodynamic comparison employ-
ing a single-chain FSH analogue containing a comparable
tether but devoid of N-linked consensus sequences to clarify
this issue.
rhFSH-N2, with two additional N-oligosaccharides, dis-
played similar in-vivo characteristics (pharmacokinetics and
pharmacodynamics) compared with rhFSH-CTP, which con-
tains four O-linked carbohydrates in the CTP tether. This is not
unexpected, as N-oligosaccharides tend to be more complex
and highly branched than O-linked moieties. However, mass
spectrometric analysis is required to characterize the carbohy-
drates of these modi®ed FSH species, as size (particularly of O-
linked oligosaccharides) can be highly variable. The effect of
carbohydrate mass, volume and/or spatial constitution on half-
life and bioactivity of FSH analogues remains speculative,
pending the outcome of comparative analyses of species with
well-characterized carbohydrate constituents.
Others have shown that carbohydrate variability within
native preparations of FSH can have an effect on half-life.
More acidic, sialic acid-rich isoforms have longer half-lives
(Blum and Gupta, 1985). In-vivo bioactivity of standard
recombinant preparations is correlated with a more acidic pI
(Mulders et al.,1997). Increased sialic acid content of rhFSH-
N2, as suggested by a lower pI on IEF gel electrophoresis may
be a factor in its increased half-life and in-vivo bioactivity. A
complex carbohydrate characterization and further studies
using desialylated hormone may provide a more de®nitive
answer.
In conclusion, we report a novel long-acting recombinant
follitropin agonist containing an N-oligosaccharide-rich tether
between the b- and a-subunits of FSH. Further studies are
required to ascertain the clinical potential of this analogue in
patients in whom exogenous gonadotrophin therapy is indi-
cated. The immunogenicity of our analogue, and its effects on
clinical parameters such as folliculogenesis, oocyte quality,
embryo development, implantation and pregnancy, and
spermatogenesis remain to be de®ned. The utility of this
approach in the development of additional FSH and other
recombinant protein analogues is promising, and merits further
investigation.
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